

Karrmann Sandra R
 Form 3
 March 11, 2019

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *		2. Date of Event Requiring Statement	3. Issuer Name and Ticker or Trading Symbol	
Karrmann Sandra R		(Month/Day/Year)	TENET HEALTHCARE CORP [THC]	
(Last)	(First)	(Middle)	03/01/2019	
1445 ROSS AVENUE, SUITE 1400			4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)			(Check all applicable)	
DALLAS, TX 75202			<input type="checkbox"/> Director <input type="checkbox"/> 10% Owner	6. Individual or Joint/Group Filing(Check Applicable Line)
(City)	(State)	(Zip)	<input checked="" type="checkbox"/> Officer <input type="checkbox"/> Other	<input checked="" type="checkbox"/> Form filed by One Reporting Person
			(give title below) (specify below)	<input type="checkbox"/> Form filed by More than One Reporting Person
			EVP and Chief HR Officer	

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	2,971	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
--	--	---	--	--	---

Edgar Filing: Karrmann Sandra R - Form 3

	Date Exercisable	Expiration Date		Amount or Number of Shares		or Indirect (I) (Instr. 5)	
2018 February Restricted Stock Units	Â (1)	Â (1)	Common Stock (2)	8,091	\$ (2)	D	Â
2018 February Performance Stock Options (Right to Buy)	Â (3)	02/28/2028	Common Stock	28,313	\$ 20.6	D	Â
2019 February Restricted Stock Units	Â (4)	Â (4)	Common Stock (2)	9,437	\$ (2)	D	Â
2019 February Performance Stock Options (Right to Buy)	Â (5)	02/27/2029	Common Stock	21,351	\$ 28.26	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Karrmann Sandra R 1445 ROSS AVENUE SUITE 1400 DALLAS, TX 75202	Â	Â	Â EVP and Chief HR Officer	Â

Signatures

Anthony L. Shoemaker, as Attorney-in-Fact for Sandra R. Karrmann 03/11/2019

**Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Half of these time-based restricted stock units vest on each of February 28, 2020 and 2021.

(2) Restricted stock units are settled in shares of the Company's common stock upon vesting.

(3) These performance-based stock options will vest on February 28, 2021, as the stock price performance condition has been satisfied.

(4) One-third of these time-based restricted stock units vest on each of February 27, 2020, 2021 and 2022.

These performance-based stock options vest on February 27, 2022, subject to the satisfaction of a stock price performance condition (5) requiring the Company's common stock price to close at or above \$35.33 per share for any 20 consecutive trading days during the three-year period following the date of grant, which was February 27, 2019.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.